Be Bio’s Hemophilia B Treatment Gains FDA Orphan Drug Status

The FDA has granted orphan drug designation to Be Biopharma’s (Be Bio) BE-101 for the treatment of hemophilia B. A new engineered B Cell medicine, BE-101 is designed to deliver the human FIX gene into primary human B cells, enabling the expression of active FIX to manage haemophilia B.
[Pharmaceutical Technology]
Press Release